Start Phase 1 clinical trial of PRT13722 in HR+/HER2- breast cancer patients
Deadline not yet reached (65 days left)
- Announced
- 10 Sep 2026
- Due
- 31 Dec 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 1 study of PRT13722 in patients with HR+/HER2- breast cancer anticipated to being enrolling in the fourth quarter”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Language
- Expected (“expects”, “plans”)
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Prelude Therapeutics Inc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-PRLD-000634 · Corrections policy